Clear cell renal cell carcinoma combined with multiple myeloma: A case report and literature review

doi:10.3969/j.issn.1004-583X.2024.11.010

Abstract

Abstract:

Objective To investigate the clinical features of clear cell renal cell carcinoma (ccRCC) combined with multiple myeloma (MM), and the basis and possibility of co-treatment. Methods The clinical data of one patient in the Hematology Department of Hebei Medical University Third Hospital were analyzed retrospectively.Results A 52-year-old male developed low back pain 2.5 years after the operation of ccRCC, and diagnosed as ccRCC combined with MM by a series examination. Treatment plan incorporated both ccRCC and MM. Induction regimen containing bortezomib and lenalidomide (analogs and upgraded versions of thalidomide) and maintenance therapy with lenalidomide were given, yielding a stable condition of both ccRCC and MM during the follow-up period. Conclusion ccRCC shares a common pathogenic pathway with MM. There may have a basis for the co-treatment of ccRCC and MM.

Key words: carcinoma, renal cell, multiple myeloma, treatment

CLC Number:

Wang Jiaqi, Meng Jianbo, Song Xiaoning, Zhang Jinqiao, Zang Meirong, Lu Jiapei, Suo Jing. Clear cell renal cell carcinoma combined with multiple myeloma: A case report and literature review[J]. Clinical Focus, 2024, 39(11): 1021-1025.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.11.010

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I11/1021

Figures/Tables 4

Fig. 1 Bone marrow image visualizing the sign of multiple myeloma (H&E staining, magnification ×100)

Fig. 2 H&E and PAS staining of bone marrow biopsy pathologically confirmed plasma cell tumors; Immunohistochemistry visualizing Kappa (+) and Lambda (-) (magnification ×100)

Fig 3 H&E staining of L1 mass confirmed metastatic ccRCC with plasma cell tumor; Immunohistochemistry visualizing Kappa (+) and Lambda (-) (magnification ×100)

Fig 4 H&E staining of bone marrow smear after chemotherapy (magnification ×100)

References 31

[1]	Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: A retrospective cohort study[J]. BMC Cancer, 2011, 11:83. doi: 10.1186/1471-2407-11-83 pmid: 21342533
[2]	Narwal A, Ramteke P, Kumar L, et al. Renal cell carcinoma concomitant with multiple myeloma[J]. J Pathol Transl Med, 2022, 56(2):111-112. doi: 10.4132/jptm.2022.01.21 pmid: 35306777
[3]	王天钰, 杨敏. 多发性骨髓瘤合并肾透明细胞癌一例[J]. 海南医学, 2021, 32(16):2168-2170.
[4]	Padhi S, Mokkappan S, Varghese RG, et al. Plasmablastic multiple myeloma following clear cell renal cell carcinoma[J]. BMJ Case Rep, 2014, 2014:bcr2014204778.
[5]	Choueiri TK, Baz RC, McFadden CM, et al. An association between renal cell carcinoma and multiple myeloma: A case series and clinical implications[J]. BJU Int, 2008, 101(6):712-715. pmid: 17970789
[6]	Shields LB, Kalebasty AR. Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports[J]. World J Clin Oncol, 2020, 11(8):644-654. doi: 10.5306/wjco.v11.i8.644 pmid: 32879850
[7]	Padhi S, Varghese RG, Ramdas A. Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review[J]. Indian J Med Paediatr Oncol, 2013, 34(4):283-291.
[8]	杨彦, 潘志兰, 张志敏. 多发性骨髓瘤患者骨髓细胞周期素D1、D3、p21的表达及与预后的相关性研究[J]. 微循环学杂志, 2021, 31(3):58-62.
[9]	马悦, 李亚, 宫经新, 等. CyclinD1及p27蛋白在多发性骨髓瘤骨髓活检中的表达及临床意义[J]. 河北医药, 2013, 35(23):3537-3539.
[10]	陈娟, 徐永刚, 姜亚卓. Cyclin D1在肾细胞癌中的表达及其意义[J]. 现代泌尿外科杂志, 2013, 18(4):332-334.
[11]	Ozturk MA, Dane F, Kaygusuz I, et al. Synchronous renal cell carcinoma and multiple myeloma: Report of two cases and review of the literature[J]. J BUON, 2009, 14(3):511-514. pmid: 19810147
[12]	Sargın G, Yavasoglu I, Doger FK, et al. A coincidence of renal cell carcinoma and hematological malignancies[J]. Med Oncol, 2012, 29(5):3335-3338. doi: 10.1007/s12032-012-0316-7 pmid: 22843308
[13]	王霞, 孟玉莲, 顿晓熠. IL-6相关信号通路靶向药物治疗多发性骨髓瘤的研究进展[J]. 巴楚医学, 2022, 5(3):110-113.
[14]	钟雯婷, 王清水, 黄义德, 等. IL-6细胞因子家族在肾细胞癌中的研究进展[J]. 福建轻纺, 2023, (2):25-28.
[15]	辉红蕾, 周晋宇, 段秋婷, 等. 多发性骨髓瘤的信号通路及其靶向治疗的研究进展[J]. 现代肿瘤医学, 2022, 30(10):1902-1906.
[16]	吕毅, 罗志刚. 核转录因子-κB与肾癌的研究进展[J]. 临床合理用药杂志, 2014, 7(5):171-172.
[17]	Sun J, Chen F, Wu G. Role of NF-κB pathway in kidney renal clear cell carcinoma and its potential therapeutic implications[J]. Aging (Albany NY), 2023, 15(20):11313-11330.
[18]	董喜凤, 宋强, 邵宗鸿. VEGF及其受体在多发性骨髓瘤发病机制中的作用及临床意义[J]. 药品评价, 2012, 9(12):4-9.
[19]	姜春霞. 肾细胞癌组织中VEGF和PDGF的表达[J]. 肿瘤基础与临床, 2015, 28(6):480-482.
[20]	Ojha RP, Evans EL, Felini MJ, et al. The association between renal cellcarcinoma and multiple myeloma: Insights from population-based data[J]. BJU Int, 2011, 108(6):825-830.
[21]	Tzeng HE, Lin CL, Tsai CH, et al. Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: A Taiwan population-based study[J]. PLoS One, 2013, ;8(7):e68041.
[22]	Amato RJ. Thalidomide therapy for renal cell carcinoma[J]. Crit Rev Oncol Hematol, 2003, 46 Suppl:S59-65.
[23]	江炜, 罗萍. 来那度胺治疗多发性骨髓瘤的临床疗效及其安全性[J]. 临床合理用药杂志, 2021, 14(21):30-32.
[24]	姜文华, 姜达. 沙利度胺对人肾癌细胞增殖及碱性成纤维细胞生长因子表达的影响[D]. 石家庄: 河北医科大学, 2007.
[25]	Yao X, Hong JH, Nargund AM, et al. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma[J]. Nat Cell Biol, 2023, 25(5):765-777. doi: 10.1038/s41556-023-01122-y pmid: 37095322
[26]	Amato RJ, Hernandez-McClain J, Saxena S, et al. Lenalidomide therapy for metastatic renal cell carcinoma[J]. Am J Clin Oncol, 2008, 31(3):244-249.
[27]	Patel PH, Kondagunta GV, Schwartz L, et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma[J]. Invest New Drugs, 2008, 26(3):273-276.
[28]	Hov H, Tian E, Holien T, et al. c-Met signaling promotes IL-6-induced myeloma cell proliferation[J]. Eur J Haematol, 2009, 82(4):277-287. doi: 10.1111/j.1600-0609.2009.01212.x pmid: 19187270
[29]	Padhi S, Sahoo PK, Banerjee D, Ghosh RN. Renal cell carcinoma and plasma cell myeloma: Unique association and clinical implications[J]. Urol Ann, 2014, 6(3):252-256. doi: 10.4103/0974-7796.134292 pmid: 25125903
[30]	Wang Y, Suarez ER, Kastrunes G, et al. Evolution of cell therapy for renal cell carcinoma[J]. Mol Cancer, 2024, 23(1):8. doi: 10.1186/s12943-023-01911-x pmid: 38195534
[31]	徐丽秀, 倪伟建, 王伟, 等. m6A甲基化修饰在肾细胞癌中的研究进展[J]. 安徽医科大学学报, 2023, 58(12):2159-2164.